Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos
Open Access
- 25 August 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 146 (1) , 146-158
- https://doi.org/10.1111/j.1365-2249.2006.03181.x
Abstract
Activated T lymphocytes either stimulate or inhibit osteoclastogenesis from haematopoietic progenitors in different experimental models. To address this controversy, we used several modes of T lymphocyte activation in osteoclast differentiation − mitogen-pulse, anti-CD3/CD28 stimulation and in vivo and in vitro alloactivation. Osteoclast-like cells were generated from non-adherent immature haematopoietic monocyte/macrophage progenitors in murine bone-marrow in the presence of receptor activator of nuclear factor (NF)-κB ligand (RANKL) and monocyte–macrophage colony-stimulating factor (M-CSF). All modes of in vivo and in vitro T lymphocyte activation and both CD4+ and CD8+ subpopulations produced similar inhibitory effects on osteoclastogenesis paralleled by enhanced dendritic cell (DC) differentiation. Osteoclast-inhibitory effect was associated with T lymphocyte activation and not proliferation, and could be replaced by their culture supernatants. The stage of osteoclast differentiation was crucial for the inhibitory action of activated T lymphocytes on osteoclastogenesis, because the suppressive effect was visible only on early osteoclast progenitors but not on committed osteoclasts. Inhibition was associated specifically with increased granulocyte–macrophage colony-stimulating factor (GM-CSF) expression by the mechanism of progenitor commitment toward lineages other than osteoclast because activated T lymphocytes down-regulated RANK, CD115, c-Fos and calcitonin receptor expression, and increased differentiation towards CD11c-positive DC. An activated T lymphocyte inhibitory role in osteoclastogenesis, confirmed in vitro and in vivo, mediated through GM-CSF release, may be used to counteract activated bone resorption mediated by T lymphocyte-derived cytokines in inflammatory and immune disorders. We also demonstrated the importance of alloactivation in osteoclast differentiation and the ability of cyclosporin A to abrogate T lymphocyte inhibition of osteoclastogenesis, thereby confirming the functional link between alloreaction and bone metabolism.Keywords
This publication has 40 references indexed in Scilit:
- Gene array identification of osteoclast genes: Differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factorJournal of Cellular Biochemistry, 2004
- Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunologyThe Keio Journal of Medicine, 2004
- Kinetics of Cytokine Gene Expression in Human CD4+ and CD8+ T‐Lymphocyte Subsets Using Quantitative Real‐Time PCRScandinavian Journal of Immunology, 2003
- The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesisJournal of Bone and Mineral Metabolism, 2003
- Resting T cells negatively regulate osteoclast generation from peripheral blood monocytesBone, 2003
- Osteoclast differentiation and activationNature, 2003
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.Journal of Clinical Investigation, 1998
- Signals for Activation of the GM-CSF Promoter and Enhancer in T CellsCritical Reviews in Immunology, 1997
- c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone RemodelingScience, 1994